Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia

[1]  R. CuestaBarriuso.  Effectiveness of Physiotherapy in the Treatment of Hemophilic Arthropathy a Systematic Review , 2017 .

[2]  J. Gu,et al.  The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[3]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[4]  A. Chuansumrit,et al.  Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  R. Sudevan,et al.  Low‐dose prophylaxis for children with haemophilia in a resource‐limited setting in south India—A clinical audit report , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  H. Elmahmoudi,et al.  Low dose prophylaxis in Tunisian children with haemophilia , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  Flora Peyvandi,et al.  The past and future of haemophilia: diagnosis, treatments, and its complications , 2016, The Lancet.

[8]  V. Ramanan,et al.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.

[9]  T. Dutta,et al.  A randomized study of very low‐dose factor VIII prophylaxis in severe haemophilia – A success story from a resource limited country , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  R. Kadir,et al.  Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta‐analysis of the literature , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  R. Jora,et al.  Clinical profile of hemophilia patients in Jodhpur Region , 2016, Asian journal of transfusion science.

[12]  M. DeBaun,et al.  A cross‐sectional study of bleeding phenotype in haemophilia A carriers , 2015, British journal of haematology.

[13]  C. Kempton,et al.  Toward optimal therapy for inhibitors in hemophilia. , 2014, Blood.

[14]  S. Assmann,et al.  Rituximab for treatment of inhibitors in haemophilia A , 2014, Thrombosis and Haemostasis.

[15]  K. Ghosh,et al.  The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients , 2014, Indian Journal of Hematology and Blood Transfusion.

[16]  V. Jiménez‐Yuste,et al.  Third Åland islands conference on von Willebrand disease, 26–28 September 2012: meeting report , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  J. Astermark,et al.  Recommendations for assessment, monitoring and follow‐up of patients with haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  M. Margaglione,et al.  F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. , 2012, Blood.

[20]  C. Kempton,et al.  How we treat a hemophilia A patient with a factor VIII inhibitor. , 2009, Blood.

[21]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[22]  A. Tefferi,et al.  How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. , 2007, Mayo Clinic proceedings.

[23]  R. Leslie,et al.  Modern management of haemophilic arthropathy , 2007 .

[24]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[25]  P. Green,et al.  Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. , 2002, Blood.

[26]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[27]  P. Garzone,et al.  Clinical evaluation of recombinant factor IX. , 1998, Seminars in hematology.

[28]  B. Nielsen,et al.  Recombinant Factor IX , 1997, Thrombosis and Haemostasis.